- Home
- LMT vs GILD Comparison
LMT vs GILD Comparison
Compare LMT & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LMT
- GILD
- Stock Information
- Founded
- LMT 1912
- GILD 1987
- Country
- LMT United States
- GILD United States
- Employees
- LMT N/A
- GILD N/A
- Industry
- LMT Military/Government/Technical
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LMT Industrials
- GILD Health Care
- Exchange
- LMT Nasdaq
- GILD Nasdaq
- Market Cap
- LMT 121.6B
- GILD 113.0B
- IPO Year
- LMT N/A
- GILD 1992
- Fundamental
- Price
- LMT $486.35
- GILD $92.98
- Analyst Decision
- LMT Buy
- GILD Buy
- Analyst Count
- LMT 11
- GILD 26
- Target Price
- LMT $624.09
- GILD $96.71
- AVG Volume (30 Days)
- LMT 1.3M
- GILD 6.4M
- Earning Date
- LMT 01-21-2025
- GILD 02-11-2025
- Dividend Yield
- LMT 2.75%
- GILD 3.38%
- EPS Growth
- LMT 0.98
- GILD N/A
- EPS
- LMT 27.67
- GILD 0.10
- Revenue
- LMT $71,295,000,000.00
- GILD $28,299,000,000.00
- Revenue This Year
- LMT $6.49
- GILD $6.54
- Revenue Next Year
- LMT $3.91
- GILD N/A
- P/E Ratio
- LMT $17.33
- GILD $937.76
- Revenue Growth
- LMT 5.33
- GILD 3.31
- 52 Week Low
- LMT $413.92
- GILD $62.07
- 52 Week High
- LMT $618.95
- GILD $98.90
- Technical
- Relative Strength Index (RSI)
- LMT 19.92
- GILD 52.30
- Support Level
- LMT $477.31
- GILD $90.27
- Resistance Level
- LMT $520.56
- GILD $93.59
- Average True Range (ATR)
- LMT 7.05
- GILD 2.12
- MACD
- LMT -1.76
- GILD -0.21
- Stochastic Oscillator
- LMT 6.36
- GILD 50.91
About LMT Lockheed Martin Corporation
Lockheed Martin is the world's largest defense contractor and has dominated the Western market for high-end fighter aircraft since it won the F-35 Joint Strike Fighter program in 2001. Lockheed's largest segment is aeronautics, which derives upward of two-thirds of its revenue from the F-35. Lockheed's remaining segments are rotary and mission systems, mainly encompassing the Sikorsky helicopter business; missiles and fire control, which creates missiles and missile defense systems; and space systems, which produces satellites and receives equity income from the United Launch Alliance joint venture.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).